In the Claims:

Amend Claims 3-10, 13, 14, and 16 to read as follows:

3. (Amended) The purified arabinogalactan composition of Claim 1 (that is) isolated from *Astragalus membranaceus* plants grown in Inner Mongolia or Shanxi province, Peoples' Republic of China.

4. (Amended) The purified arabinogalactan composition of Claim 1 where the *Astragalus membranaceus* plants are two-year old *Astragalus membranaceus* plants.

5. (Amended) The purified arabinogalactan composition of Claim 1 having a weight average molecular weight of 20 kiloDaltons to 60 kiloDaltons.

6. (Amended) The purified arabinogalactan composition of Claim 1 having an arabinose/galactose ratio of at least 1.5.

7. (Amended) The purified arabinogalactan composition of Claim 1 having an endotoxin content of not more than 1.0 EU/mg.

8. (Amended) An arabinogalactan protein composition, having a weight average molecular weight of at least 100 kiloDaltons, isolated from a purified arabinogalactan composition of Claim 1.

9. (Amended) An aqueous intravenously injectable arabinogalactan formulation comprising:
(a) a therapeutically effective amount of the purified arabinogalactan composition of Claim 1; and
(b) an aqueous intravenously injectable excipient.

10. (Amended) A method of treating a disease state in a mammal capable of treatment by administration of the purified

arabinogalactan composition of Claim 1, comprising intravenously administering to the mammal an effective amount of the purified arabinogalactan composition of Claim 1.

13. (Amended) The method of Claim 10 where the mammal is a human.

14. (Amended) The method of Claim 12 where the mammal is suffering from bone marrow suppression.

16. (Amended) The method of Claim 10 further comprising the administration of at least one other therapeutic agent.